Comparative Pharmacology
Head-to-head clinical analysis: HUMULIN N versus HUMULIN R KWIKPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMULIN N versus HUMULIN R KWIKPEN.
HUMULIN N vs HUMULIN R KWIKPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin isophane (NPH) is an intermediate-acting insulin that lowers blood glucose by promoting peripheral glucose uptake, especially in muscle and adipose tissue, and inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase activity and downstream signaling pathways.
Insulin lispro lowers blood glucose by binding to insulin receptors, increasing glucose uptake in skeletal muscle and adipose tissue, and inhibiting hepatic glucose production.
0.5-1 unit/kg/day subcutaneously, divided into 2 doses (morning and evening).
Subcutaneous injection, individualize based on metabolic needs and blood glucose monitoring. Typical starting total daily insulin dose in type 1 diabetes: 0.5-1 unit/kg/day, with 50-60% as basal and 40-50% as prandial. In type 2 diabetes, initial total daily dose: 0.2-0.4 units/kg/day, with adjustments. Administer 30 minutes before meals.
None Documented
None Documented
Terminal half-life: 1.5-2.5 hours (subcutaneous); longer in renal impairment.
5-10 minutes (intravenous); subcutaneous: 1.5-2 hours (depot absorption-limited).
Renal: 60-80% as intact insulin; hepatic and renal clearance; negligible biliary/fecal elimination.
Renal: 60-80% (metabolized to inactive peptides); hepatic metabolism via insulin-degrading enzyme; remainder reabsorbed in proximal tubule.
Category C
Category C
Human Insulin
Human Insulin